Transarterial chemoembolization combined with apatinib in the treatment of advanced hepatocellular carcinoma: a prospective, multi-center, real-world study (Ahend-HAP02) ...

Japanese drugmaker Eisai revealed that its in-house discovered tyrosine kinase inhibitor, Lenvima (lenvatinib mesylate), in combination with the anti-PD-1 antibody, pembrolizumab, and transarterial ...

Transcatheter arterial chemoembolization (TACE) is thought to prevent recurrence, but its efficacy is a matter of controversy. 4 OBJECTIVES To analyze the effect of preventive TACE on recurrence rates ...

Due to the increasing rate of obesity, cases of liver cancer are expected to double by 2050. This claim has been made in a ...

TACE combined with SBRT enhanced survival rates in patients with large hepatocellular carcinoma tumors, offering promising ...

On Wednesday, she will make her way to the Frankfurt University Hospital for her latest appointment with German radiologist, ...

Stage 4 oesophageal cancer is an advanced form of the disease in which cancer has spread beyond the oesophagus to distant ...

Median follow-up was about 6.7 years in both groups. The 5-year OS was 79.8% in the surgery group and 78% in the RFA group.

随着艺妙神州与宇树科技两家被投企业接连启动IPO进程，首程控股正迎来从战略投入到资本回报的关键转折点。而公司在资本市场上的主动回购行为，也恰恰展现了其对内在价值释放节奏的精准把握。在港股估值持续分化、投资者信心波动的大环境下，首程控股以连续回购的实际行动，回应市场关注、稳定市场预期。配合下半年即将举行的世界机器人大会与人形机器人运动会，公司有望借助多重利好催化，推动产业落地与估值修复共振。

Corina Dutcus, SVP, oncology global clinical development lead at Eisai, discusses the potential of the E7386 and lenvatinib combination to address unmet needs in second-line treatment for endometrial ...

回购是上市公司最具信号意义的资本动作之一。面对短期市场波动，首程控股选择主动出击、坚定回购，释放出强烈的管理层态度：公司将持续秉持对股东负责、对长期价值负责的理念，坚决捍卫企业基本面与市场信心。

The public health system in England offered me palliative care. It was a death sentence I wasn't willing to accept. I wasn't ready to leave behind my six children: Matt, 35; Will, 24; Hannah, 19; ...